OXBDF (Oxford BioMedica) Asset Impairment Charge: $0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OXBDF Oxford BioMedica PLC OXBDF
71 GF Score
Price $7.15
GF Value $6.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Asset Impairment Charge?

Oxford BioMedica OXBDF 71 Asset Impairment Charge is $0.0 Mil as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $6.82 (Fairly Valued). The stock has 5 warning signs investors should review.

Oxford BioMedica's Asset Impairment Charge for the six months ended in Dec. 2025 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 was $0.0 Mil.

Oxford BioMedica Asset Impairment Charge Related Terms

Oxford BioMedica Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Asset Impairment Charge Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OXBDF
71GF Score
Oxford BioMedica PLC OXBDF
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Asset Impairment Charge of $0.0 Mil mean?
Oxford BioMedica (OXBDF) has a Asset Impairment Charge of $0.0 Mil as of Dec. 2025.
Is Oxford BioMedica's Asset Impairment Charge too high?
Oxford BioMedica's current Asset Impairment Charge is $0.0 Mil. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Asset Impairment Charge compare to VRTX and REGN?
Oxford BioMedica's Asset Impairment Charge of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Oxford BioMedica's current Asset Impairment Charge is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Fairly Valued. The stock's GF Value™ is $6.82, compared to a current price of $7.15 — trading 4.8% above its estimated fair value. The current Asset Impairment Charge is $0.0 Mil. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Asset Impairment Charge is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.15 is trading 4.8% above its estimated GF Value™ of $6.82. GuruFocus considers Oxford BioMedica to be Fairly Valued.

Key valuation signals for OXBDF:

  • Asset Impairment Charge: $0.0 Mil
  • GF Value™: $6.82 vs. price of $7.15 (4.8% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score

Get the complete analysis for OXBDF

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.15
Price
$6.82
GF Value